Skip to main content

Impact of Neck PET/CT Positivity on Survival Outcomes-Visual and Quantitative Assessment: Results From ACRIN 6685.

Publication ,  Journal Article
Stack, BC; Duan, F; Romanoff, J; Sicks, JD; Subramaniam, RM; Lowe, VJ
Published in: Clin Nucl Med
February 1, 2023

INTRODUCTION: FDG PET/CT was prospectively studied in 287 cN0 head and neck cancer patients in ACRIN 6685, and additional analysis of neck FDG uptake upon recurrence-free survival (RFS) and overall survival (OS) was performed. PATIENTS AND METHODS: Two hundred eight had analyzable data. Survival analysis was performed to compare RFS and OS based on neck FDG visual assessment (VA) and SUV max . For SUV max , the optimal thresholds were calculated using conditional inference trees on a randomly selected 70% training data set and validated using the remaining 30% of data. Kaplan-Meier curves with log-rank tests were generated for the patient groups based on VA and optimal SUV max thresholds, and the hazards ratios (HRs) and 95% confidence intervals (CIs) were also calculated. Hypothesis testing was set at a significance level of 0.05. RESULTS: A total of 73.9% of bilateral cN0 and 50.0% of unilateral cN0 were alive at the end of the study with the remaining being dead or lost to follow-up. Overall survival median follow-up time was 24.0 months (interquartile range, 15.8-25.3; range, 0-37.0). A total of 63.3% of bilateral cN0 and 42.5% of unilateral cN0 patients remained disease free during the study. Recurrence-free survival median follow-up time was 23.9 months (interquartile range, 12.4-25.2; range, 0-35.6). Visual assessment of necks by our panel of radiologists was significantly associated with RFS (HR [95% CI], 2.30 [1.10-4.79]; P = 0.02), but not with OS (HR [95% CI], 1.64 [0.86-3.14]; P = 0.13). The optimal SUV max thresholds were 2.5 for RFS and 5.0 for OS. For SUV max assessment, applying the optimal thresholds to the 30% test data yielded HRs (95% CIs) of 2.09 (0.61-7.14; P = 0.23) for RFS and 3.42 (1.03-11.41; P = 0.03) for OS. The SUV max threshold of 5.0 was significantly associated with RFS (HR [95% CI], 5.92 [1.79-19.57]; P < 0.001). CONCLUSIONS: Neck FDG uptake by VA is significant for RFS. An SUV max threshold of 5.0 is significantly associated with OS and RFS.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Nucl Med

DOI

EISSN

1536-0229

Publication Date

February 1, 2023

Volume

48

Issue

2

Start / End Page

126 / 131

Location

United States

Related Subject Headings

  • Tomography, X-Ray Computed
  • Retrospective Studies
  • Prognosis
  • Positron-Emission Tomography
  • Positron Emission Tomography Computed Tomography
  • Nuclear Medicine & Medical Imaging
  • Multimodal Imaging
  • Humans
  • Fluorodeoxyglucose F18
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Stack, B. C., Duan, F., Romanoff, J., Sicks, J. D., Subramaniam, R. M., & Lowe, V. J. (2023). Impact of Neck PET/CT Positivity on Survival Outcomes-Visual and Quantitative Assessment: Results From ACRIN 6685. Clin Nucl Med, 48(2), 126–131. https://doi.org/10.1097/RLU.0000000000004483
Stack, Brendan C., Fenghai Duan, Justin Romanoff, JoRean D. Sicks, Rathan M. Subramaniam, and Val J. Lowe. “Impact of Neck PET/CT Positivity on Survival Outcomes-Visual and Quantitative Assessment: Results From ACRIN 6685.Clin Nucl Med 48, no. 2 (February 1, 2023): 126–31. https://doi.org/10.1097/RLU.0000000000004483.
Stack BC, Duan F, Romanoff J, Sicks JD, Subramaniam RM, Lowe VJ. Impact of Neck PET/CT Positivity on Survival Outcomes-Visual and Quantitative Assessment: Results From ACRIN 6685. Clin Nucl Med. 2023 Feb 1;48(2):126–31.
Stack, Brendan C., et al. “Impact of Neck PET/CT Positivity on Survival Outcomes-Visual and Quantitative Assessment: Results From ACRIN 6685.Clin Nucl Med, vol. 48, no. 2, Feb. 2023, pp. 126–31. Pubmed, doi:10.1097/RLU.0000000000004483.
Stack BC, Duan F, Romanoff J, Sicks JD, Subramaniam RM, Lowe VJ. Impact of Neck PET/CT Positivity on Survival Outcomes-Visual and Quantitative Assessment: Results From ACRIN 6685. Clin Nucl Med. 2023 Feb 1;48(2):126–131.

Published In

Clin Nucl Med

DOI

EISSN

1536-0229

Publication Date

February 1, 2023

Volume

48

Issue

2

Start / End Page

126 / 131

Location

United States

Related Subject Headings

  • Tomography, X-Ray Computed
  • Retrospective Studies
  • Prognosis
  • Positron-Emission Tomography
  • Positron Emission Tomography Computed Tomography
  • Nuclear Medicine & Medical Imaging
  • Multimodal Imaging
  • Humans
  • Fluorodeoxyglucose F18
  • 3202 Clinical sciences